Zoeken
Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy
September 18, 2018
Atzmon A, Herrero M, Sharet-Eshed R, Gilad Y, Senderowitz H, Elroy-Stein O.
Front Mol Neurosci. 2018;11:336. Published 2018 Sep 18. doi:10.3389/fnmol.2018.00336
Vanishing white matter: deregulated integrated stress response as therapy target
June 28, 2021
Abbink TEM, Wisse LE, Jaku E, Thiecke MJ, Voltolini-González D, Fritsen H, Bobeldijk S, Ter Braak TJ, Polder E, Postma NL, Bugiani M, Struijs EA, Verheijen M, Straat N, van der Sluis S, Thomas AAM, Molenaar D, van der Knaap MS.
Ann Clin Transl Neurol. 2019 Aug;6(8):1407-1422. doi: 10.1002/acn3.50826. Epub 2019 Jul 18. PMID: 31402619; PMCID: PMC6689685.
Identification of repurposable cytoprotective drugs in vanishing white matter disease patient-derived cells
August 5, 2021
Ng, N., Cabral-da-Silva, M.C., Maksour, S. et al.
transl med commun 5, 18 (2020). https://doi.org/10.1186/s41231-020-00071-0